Establishments described in this report are primarily participating in the telehealth market. Telehealth is the distribution of health-related services and information via electronic information and telecommunication technologies. It allows long-distance patient and clinician contact, care, advice, reminders, education, intervention, monitoring, and remote admissions.

Establishments described in this report are primarily participating in the teleradiology market. Teleradiology is the transmission of radiological patient images, such as x-rays, CTs, and MRIs, from one location to another for the purposes of sharing studies with other radiologists and physicians. Teleradiology is a growth technology given that imaging procedures are growing approximately 15% annually against an increase of only 2% in the radiologist population.

我们看好流感疫苗2022 年景气度反转：1）近期随着群体屏障弱化与新冠流行缓和，流感在南半球与中国南方已存在抬头趋势；2）2022 年中国流感疫苗产能大幅扩张且供应充分前置（5M22 已获批签发且2Q22 销售），龙头产能与销量均领先；3）中国流感疫苗2019-2020 产销率在80%~85%，2021年因新冠疫苗接种挤压降至50%以下，我们预计受益于疫情警醒、供应前置、挤兑弱化等因素2022 年需求有望V 型复苏并显著超过2020-2021 年。产业链相关公司华兰生物/华兰疫苗、百克生物、金迪克。

2022H1，医药整体依然处于低位震荡估值消化中，4月底前回调明显且后续反弹力度较弱，主要还是医药整体前几年估值扩张严重同时政策面混沌也有所加剧。2022H1医药占沪深总成交额比例主要在7-15%之间，但考虑医药交易量中新冠占比较大，预计剔除新冠后医药主体交易持续低迷。截至2022Q1非医药主动型基金连续7个季度低配，医药悲观情绪持续演绎，但考虑2022Q2市场整体波动较大，预计当前医药持仓情况相比2022Q1也有较大变化。